Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 11/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.46 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.46 |
| ▸ | PYGM | P11217 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3498860 | 1.00 | CDA (0.67) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL23240639 | 1.00 | CDA (0.67) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL25824030 | 1.00 | CDA (0.67) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL27055218 | 1.00 | CDA (0.67) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL25824033 | 0.87 | CDA (0.51) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL27055220 | 0.87 | CDA (0.51) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL583301 | 0.80 | CDA (1.00) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL587033 | 0.80 | CDA (1.00) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL586993 | 0.80 | CDA (1.00) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL11312120 | 0.80 | CDA (1.00) | CDAMAPTSLC28A1SLC28A2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004037159-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING FAT METABOLISM | OBETHERAPY BIOTECHNOLOGY (FR) | 2004-05-06 | — | — | WO | disclosed |